Effect of gut microbiota-mediated tryptophan metabolism on inflammaging in frailty and sarcopenia

YuShuang Xu,Tao Mao,YouJun Wang,XingSi Qi,WenJun Zhao,Hao Chen,CuiPing Zhang,XiaoYu Li,Yu Shuang Xu,You Jun Wang,Xing Si Qi,Wen Jun Zhao,Cui Ping Zhang,Xiao Yu Li
DOI: https://doi.org/10.1093/gerona/glae044
2024-02-15
Abstract:Abstract Frailty syndrome refers to the nonspecific state of increased body vulnerability and decreased antistress and recovery abilities after stress during aging. Sarcopenia is the major component of frailty and is characterized by the gradual loss of muscle mass, strength, and function with age. Inflammaging is the gradual increase in inflammatory status during aging, and it disrupts immune tolerance, causes physiological changes in tissues, organs, and normal cells, and is related to frailty and sarcopenia. The gut microbiota is an extremely complex and diverse microbial community that coevolves with the host. The composition and structure of the gut microbiota and the metabolism of tryptophan (Trp) significantly change in older adults with frailty and sarcopenia. The gut microbiota participates in regulating the Trp metabolic pathways of kynurenine (Kyn), 5-hydroxytryptamine (5-HT), and indole in the gastrointestinal tract. The Trp metabolites derived from the gut microbiota may synergistically promote the occurrence of age-related frailty and sarcopenia by promoting inflammation in the intestines, nervous system, and muscles. The role and mechanisms of the gut microbiota, Trp metabolism, and inflammaging in age-related frailty and sarcopenia may be a worthwhile research direction to help promote healthy aging.
What problem does this paper attempt to address?